Yo! Technology. What is it all about?

How do we get the majority of people on a super-duper-safe preventative medicine

that helps them live a longer, healthier life? And I think if we can get anywhere

directly near that, of course for dogs, maybe for people one day too, it would massively

benefit society.

Hello and welcome to Danny in the Valley,

your weekly dispatch from behind the scenes and inside the minds of the top people in tech.

I am your host as ever.

Danny Fortson, the West Coast correspondent for the Sunday Times.

And as always, I'm coming to you from beautiful Oakland, California.

This week, I want to talk not about AI. I want to talk about dogs. More specifically,

let's talk about dogs living a lot longer than they do currently. That is what Celine Halewa is working on. And she is our guest this week. She is the founder and CEO of Loyal, which is a

startup that has raised $58 million. And what they're doing is developing multiple drugs that

she hopes will soon be approved as treatments, really the first, the very first ever treatment,

specifically for the indication of life extension or health span extension

for man's best friend. Now, you may be asking right now, why the hell is she doing that? Why not

focus on, you know, people? Well, she's doing that too. The goal here is to target the same

biological pathways in dogs that affect humans goal here is to target the same biological pathways in

dogs that affect humans. In other words, the same kind of mechanisms that make us kind of old

and decrepit and demented or whatever, a lot of those same kind of mechanisms are at work in dogs.

So the idea is if you can prove that it works first in canines, then it's easier to transfer it over to humans. That's the idea. I am sure you have

lots of questions about this whole caper, but that's why you're here. Celine has a really

...